NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST

Their core work

Nottingham University Hospitals NHS Trust is one of the UK's largest acute NHS trusts, providing clinical research infrastructure embedded within a major teaching hospital. In EU projects, they contribute as a clinical trial site and clinical expertise provider — offering access to patient populations, clinical facilities, and NHS-standard care protocols. Their H2020 involvement spans respiratory palliative care (managing breathlessness in dying patients with COPD and ILD) and women's health (clinical evaluation of novel treatments for recurrent vaginal infections). Their primary value in research consortia is translational: bridging laboratory or product-stage research into real-world clinical settings with NHS credibility.

What they specialise in

How they've shifted over time

Their earliest H2020 engagement (BETTER-B, starting 2019) centred on palliative respiratory medicine — specifically managing breathlessness in patients with COPD, ILD, and other lung diseases approaching end of life, with a strong focus on caregiver impact and cost-effectiveness of clinical interventions. By 2020, their participation shifted to women's health with NEFERTITI, which addressed recurrent vaginal infections caused by candida and gardnerella, with emphasis on self-treatment, over-the-counter approaches, and resistance to conventional antimicrobials. The two projects share no topical overlap, suggesting the Trust participates opportunistically based on its broad patient access across clinical departments rather than a single strategic research theme.

Their trajectory is toward patient-facing clinical evaluation of novel therapeutic products — particularly in underserved areas (end-of-life breathlessness, recurrent vaginal infections) where NHS patient access and real-world clinical settings are the decisive contribution.

How they like to work

Nottingham University Hospitals has never led an H2020 project — all participation has been as a third party or consortium partner, reflecting a supporting rather than initiating role in EU research. This is typical of NHS trusts, which contribute clinical infrastructure, patient recruitment, and translational expertise while academic or SME partners drive project coordination. With 20 unique partners across only 2 projects, they operate within medium-to-large consortia, which is consistent with clinical trial networks that require multi-site patient recruitment.

Across two projects, Nottingham University Hospitals has collaborated with 20 unique partners spread across 10 countries, indicating exposure to genuinely European multi-site research consortia. No single geographic cluster is apparent from available data.

What sets them apart

As an NHS trust rather than a university or research institute, Nottingham University Hospitals brings something most academic partners cannot: direct access to a large, ethnically and socially diverse patient population within a publicly funded healthcare system, governed by NHS ethics and GCP frameworks. For clinical trials requiring UK patient recruitment, NHS-standard outcome data, or health economics analysis grounded in real care costs, they offer a credible and practical trial site. Their dual presence in respiratory medicine and women's health also makes them unusually versatile for health-focused consortia covering non-communicable disease management and infection control.

Highlights from their portfolio

• NEFERTITI
  The only project where the Trust received direct EC funding (EUR 114,634), addressing a commercially relevant gap — resistance-free, self-administered treatment for recurrent vaginal infections — at the intersection of antimicrobial resistance policy and women's health innovation.
• BETTER-B
  A large RIA-funded multi-year trial (2019–2023) on breathlessness in palliative care, where the Trust contributed as a third-party clinical site — demonstrating their role as an established node in European end-of-life care research networks.